At a glance
ClinicalIndex Comparison RecordN/ACompleted· 151 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab
In Brief
An observational study evaluating Tocilizumab for Rheumatoid Arthritis. Completed, enrolled 151 participants across 24 sites.
Detailed Summary
This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of tocilizumab therapy in a routine clinical practice in participants with moderate to severe rheumatoid arthritis (RA). Data will be collected for 6 months with a maximum study duration of 18 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedAug 2012
Primary CompletionDec 2013
TodayJul 2026
First PostedAug 14, 2012
Enrollment StartJun 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.9 years ago
Interventions
Tocilizumabdrug
Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.